Loading
Anyone diagnosed with a rare or complex cancer gets an automatic remote review by a specialist centre, paid for by the health system, before treatment starts.
Second opinions change diagnosis or management in a substantial minority of rare cancer cases (sarcoma, lymphoma subtyping, neuroendocrine tumours) and pathology discordance for rare tumours is well documented. Reference-centre networks (French NETSARC, EURACAN) show the model. The proposal is an entitlement to a remote expert review, delivered through virtual tumour boards, funded per case, with turnaround within 10 working days and the report returned to both the local team and the patient in plain language.
Shares Rare and paediatric cancers without markets, Neuroendocrine tumours, Sarcomas (soft tissue, bone, GIST).
Shares Rare and paediatric cancers without markets, Neuroendocrine tumours, Sarcomas (soft tissue, bone, GIST).
Shares Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
Shares Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
Shares Rare and paediatric cancers without markets, Neuroendocrine tumours, Sarcomas (soft tissue, bone, GIST).
Shares Patients lack understanding, navigation and agency, Sarcomas (soft tissue, bone, GIST).
Shares Rare and paediatric cancers without markets, Neuroendocrine tumours, Sarcomas (soft tissue, bone, GIST).
Shares Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).